Innate Pharma Lands $580M Lacutamab Deal with Sobi, Extends Cash Runway to Q3 2027
IPHA sits 90% above its 52-week low of $1.17 on light trading volume (0.1× avg).
Summary
Innate Pharma partners with Sobi on lacutamab, receiving $75M upfront and up to $580M in milestones, extending cash runway to Q3 2027 and enabling Phase 3 initiation. New CMO appointed to lead clinical execution.
Key Events · M&A and Partnerships · IPHA
-
Sobi Partnership for Lacutamab
Innate Pharma enters a strategic partnership with Sobi, receiving $75 million upfront and eligibility for up to $580 million in total milestones plus tiered double-digit royalties on net sales.
-
Cash Runway Extended to Q3 2027
The upfront payment extends the company's projected cash runway from Q3 2026 to Q3 2027, funding the TELLOMAK-3 Phase 3 trial and the planned accelerated approval filing in Sézary syndrome.
-
Phase 3 Trial Initiation Planned
Innate will conduct the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma, supporting accelerated approval based on existing Phase 2 data, with Sobi holding global commercialization rights.
-
New Chief Medical Officer Appointed
Markus Jensen appointed CMO effective September 1, 2026, bringing over 25 years of oncology development experience to lead late-stage clinical and regulatory execution.
Analysis · IPHA · Life Sciences
A transformative partnership with Sobi for lead asset lacutamab delivers $75 million upfront and up to $580 million in total milestones plus royalties. Critically, this non-dilutive financing extends the cash runway—previously only through Q3 2026—to Q3 2027, directly funding the pivotal TELLOMAK-3 Phase 3 trial required for accelerated approval. Leadership continuity is secured with the appointment of a new CMO to drive late-stage execution. For a company with a market cap around $164 million, the deal fundamentally reshapes the risk profile and survival outlook.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IPHA was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $163.6M. The 52-week trading range was $1.17 to $2.62. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.